CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer.The main questions i...
Phase 2
Charlotte, North Carolina, United States
doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...
Phase 3
Charlotte, North Carolina, United States and 216 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Charlotte, North Carolina, United States and 228 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Charlotte, North Carolina, United States and 508 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Charlotte, North Carolina, United States and 109 other locations
with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...
Phase 3
Charlotte, North Carolina, United States and 360 other locations
(with enzalutamide-naïve metastatic castration-resistant prostate cancer) will be randomized to receive either NUV-868 monotherapy, enzaluta...
Phase 1, Phase 2
Huntersville, North Carolina, United States of America and 30 other locations
(ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and ...
Phase 1
Huntersville, North Carolina, United States of America and 25 other locations
1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors...
Phase 1, Phase 2
Huntersville, North Carolina, United States and 5 other locations
to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast...
Phase 2
Charlotte, North Carolina, United States and 10 other locations
Clinical trials
Research sites
Resources
Legal